- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–180
of 180
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
- Interventions
- Esomeprazole, Budesonide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Baked Milk
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Etrasimod, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 85 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Cendakimab, CYP substrates
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
- Drug
- Lead sponsor
- AQILION AB
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 30 more
- Conditions
- Abdominal Pain, Inflammatory Bowel Diseases, Eosinophilic Gastroenteritis, Diarrhea, Hematochezia, Weight Loss
- Interventions
- Ondansetron
- Drug
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Esophagitis
- Interventions
- omalizumab, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease, Food Allergy
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2050
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Fluticasone Propionate, Budesonide
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio